Trefoil Therapeutics

OverviewSuggest Edit

Trefoil Therapeutics is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop regenerative pharmacologic treatments for corneal diseases. Lead candidate TTHX1114 is an engineered form of FGF-1 designed to stimulate proliferation and migration of corneal endothelial cells. The company's second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision.
TypePrivate
Founded2014
Websitetrefoiltherapeutics.com

Latest Updates

Employees (est.) (Jan 2020)7

Trefoil Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014

Trefoil Therapeutics total Funding

$33.2 m

Trefoil Therapeutics latest funding size

$28 m

Time since last funding

6 months ago

Trefoil Therapeutics investors

Trefoil Therapeutics's latest funding round in July 2019 was reported to be $28 m. In total, Trefoil Therapeutics has raised $33.2 m
Show all financial metrics

Trefoil Therapeutics Online and Social Media Presence

Embed Graph

Trefoil Therapeutics Frequently Asked Questions

  • When was Trefoil Therapeutics founded?

    Trefoil Therapeutics was founded in 2014.

  • How many employees does Trefoil Therapeutics have?

    Trefoil Therapeutics has 7 employees.

  • Who are Trefoil Therapeutics competitors?

    Competitors of Trefoil Therapeutics include Morphic Therapeutic, Twist Bioscience and Diffusion Pharmaceuticals.